john torrison president
   
  • Club Home
  • Club Members
  • Listen with Bill
    • Bill's History
  • Turntable
    • TT History
  • The FlipSide
  • Picturesque!
  • Skips Corner
  • Gulliver's Travels
  • The Club Pub
    • Sucks News
  • Harv's Corner

The Club PUBlication  01/10/2022

1/10/2022

0 Comments

 
Picture
Picture

Sleep apnea device maker doubles sales
Inspire’s implantable neurostimulator is only one on market.
​
Sleep apnea device maker doubles sales
By BURL GILYARD [email protected]

Picture


Inspire Medical Systems Inc. makes an implantable device to treat sleep apnea, but the company's financials are far from sleepy.

The Golden Valley-based company announced Tuesday after market close that its 2021 revenue would be between $233 million and$233.4 million, a robust increase of about 102% over the previous year.  In 2016, the company tallied just $16.4 million in revenue. The preliminary numbers for 2021 represent a 1,300% increase in its sales over the last five years. It ranks among the fastest-growing public companies in Minnesota.

The company said its rapid growth is fueled by high consumer demand and low — or no — competition from other device makers.  Inspire developed the firstever implantable neurostimulation device to treat obstructive sleep apnea. No one else has created a similar product and brought it to market. In its niche, Inspire Medical has zero competition.
"We are the only ones doing this," said Tim Her-bert, Inspire's chief executive.

Other companies have competing products in development, but they are still several years away from approval by the U.S. Food and Drug Administration (FDA), he said.

Until now, sleeping masks have been the standard treatment for sleep apnea. These mask devices provide continuous positive airway pressure (CPAP), but many patients find them uncomfortable.
Beyond the comfort factor, Herbert said the Inspire implant is also more effective.

The company recently received FDA approval for a Bluetooth-enabled patient remote control that pairs with the implanted device.  Inspire has been able to avoid many of the pandemic challenges faced by its medical technology peers, like delayed elective surgeries.  "How we're able to continue to grow is we are outpatient surgery," said Herbert.  "We don't take up hospital beds."

The comhepany added 81 more U.S. implanting centers to its network last quarter, more than it forecast.  

The procedure takes 90 minutes. It has the same basic technology as a pacemaker and is powered by a lithium battery which lasts 11 years.
"Importantly, our robust pace in the opening of new centers includes a growing number of [Ambulatory Surgical Centers] , which continue to increase at a higher rate than the addition of hospitals,"  Herbert said in the financial news release.
​
Inspire went public at $24 a share in April 2018. It closed Wednesday at about $237 a share, an impressive 887% increase in just three-and-a-
half years.  The financial results are preliminary and unaudited.
The company will report full financial results on Feb. 8.  But like many growth companies, Inspire Medical has yet to post a profit.
For the first nine months of 2021, Inspire reported revenue of $155 million and a net loss of $39.65 million.

The sleep apnea market is big. It's a relatively common condition in the U.S. that affects more than 30 million Americans, according to the American Sleep Apnea Association.  Untreated, it can lead to more serious conditions such as heart failure, high blood pressure and strokes.
Inspire Medical grew out of med-tech giant Medtronic in 2007.  Herbert had worked at Medtronic in a variety of management roles, including product development and clinical research.
"This is a therapy that we were not able to fund inside Medtronic. In partnership with Medtronic, we created a new company," said Herbert.
He said that Medtronic still owns a "very small" stake in the company.
"[It] started with just myself down in my basement," recalled Herbert. The company now has more than 500 employees. Herbert has been CEO since the company's inception.  Inspire began selling the product in Europe in 2011 and in the U.S. in 2014.

Herbert said that in December the company marked treating its 20,000th patient with its unique system.  Inspire Medical's treatment is available in 48 states and throughout Europe.  Herbert said that the company will soon see the first implant for cases in Japan and is looking to expand further into Asia.


Burl Gilyard • 612-673-4756
0 Comments



Leave a Reply.

    Archives

    June 2025
    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    April 2024
    March 2024
    February 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018

    RSS Feed